Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Legislation on Biosimilars
Brand-name firms ask for significant clinical trial data before approval to ensure the new versions are true copies with the closest possible safety profile and efficacy. They’d also like at least 14 years of market exclusivity to ensure the ability to generate profits after a long and costly development process. Companies focusing on biosimilars would prefer to avoid going through every clinical trial phase, stating that proving safety and efficacy can be done in a quicker manner. And of course, they want to get their biosimilars on the market asap. Politicians are currently reviewing a proposal that would confer at least five years of market exclusivity. So where do you stand?